Cervical Mesonephric Adenocarcinoma With Novel FGFR2 Mutation

Stephanie L. Skala & Kathleen R. Cho et al.

Mesonephric adenocarcinoma is a rare tumor, accounting for <1% of cervical cancers. Well-differentiated mesonephric adenocarcinoma can be difficult to distinguish from diffuse mesonephric hyperplasia. Herein, we report a case of well-differentiated mesonephric adenocarcinoma with an FGFR2 mutation not previously reported in the literature. Nonselective tyrosine kinase inhibitors or FGFR2 inhibitors may represent options for targeted therapy.

Authors
Stephanie L. Skala, Patricia A. Gregg, James W. Orr, Aaron M. Udager, Noah A. Brown, Kathleen R. Cho